Lexicon Pharmaceuticals Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Lexicon Pharmaceuticals (LXRX) reported third-quarter 2026 revenue of $11.3 million, a decrease from $14.2 million in the prior-year period. Despite the decline in total revenue, the company recognized $10 million in milestone revenue from Novo Nordisk following progress in its LX9851 obesity program. Net loss for the quarter was $14.0 million ($0.03 per share), while cash and investments grew significantly to $183.2 million as of September 30, 2026. The company provided key clinical updates, noting that SONATA-HCM enrollment has exceeded targets with 542 patients enrolled. Management expects a readout for the SONATA-HCM trial in Q1 2027 and plans to resubmit its ZYNQUISTA NDA in the same period. Additionally, Lexicon highlighted preclinical success for Pilavapadin and expansion of Inpefa through Viatris in new international markets.
Topics: clinical milestones guidance net loss obesity drug development revenue
Read the full article at Motley Fool
Part of the story InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook (23 articles)